Biogen
Statements

January 11, 2024
Update on Marketing Authorization Application for Lecanemab in the European Union

Eisai has announced an update on the regulatory review of lecanemab by the European Medicines Agency. Additional details can be found in a news release available on Eisai’s website (insert hyperlink).

October 31, 2023
JAMA Neurology Publishes Data on Biogen’s Investigational Antisense Oligonucleotide Targeting Tau

JAMA Neurology published biomarker data from the placebo-controlled period (PCP) and long-term extension phase of the BIIB080 Phase 1b study of the antisense oligonucleotide (ASO) which targets tau pre-mRNA in early-stage Alzheimer's disease (AD). The publication follows the presentation of

September 21, 2023
STATEMENT: BIOGEN PROVIDES UPDATE ON THE ACQUISITION OF REATA PHARMACEUTICALS

Biogen confirms that today Reata Pharmaceuticals announced in a special meeting the stockholders of the company voted to approve the company’s previously announced acquisition by Biogen. For more information, read Reata’s Form 8-K disclosure.

June 26, 2023
Biogen Announces 2023 Annual Shareholder Meeting Preliminary Results

Cambridge, Mass. – June 26, 2023 – Biogen Inc. (Nasdaq: BIIB) today held its Annual Meeting of shareholders. As previously announced, Caroline Dorsa has succeeded Stelios Papadopoulos as Chair of the Board of Directors at conclusion of the Annual Meeting.

June 5, 2023
Statement: Biogen Provides Update on Parkinson’s Disease Clinical Development Program

As part of its ongoing Research & Development (R&D) prioritization initiative and resource allocation, Biogen announced plans to revise the clinical development program for BIIB122, a small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2), which is being developed in collaboration with

May 3, 2023
Biogen Files Form 8-K

Biogen today filed a Form 8-K with the United States Securities and Exchange Commission, disclosing that "On May 3, 2023, the European Commission notified Biogen Inc. of its decision that the period of regulatory market protection for Tecfidera extends until February 2, 2025.”

May 1, 2023
BIOGEN PUBLISHES 2022 ESG REPORT

Biogen has published its 2022 ESG Report, which supports Biogen’s business goals by sharing our corporate responsibility story, disclosing key environmental, social, and governance (ESG) data and providing updated progress against our targets and commitments. You can find a copy here.

April 28, 2023
Biogen Announces Publication of BIIB080 Phase 1b Data in Nature Medicine

Nature Medicine has published a manuscript detailing promising results from Biogen’s multiple ascending dose Phase 1b trial, which evaluated the safety, pharmacokinetics and target engagement of Biogen’s BIIB080 (MAPT ASO), an investigational antisense oligonucleotide targeting tau mRNA in

January 23, 2023
Biogen Shares Update on FDA Advisory Committee Meeting for Tofersen

On January 23, 2023, the Federal Register  published a notice that the U.S. Food and Drug Administration (FDA) will convene a virtual meeting of the Peripheral and Central Nervous System Drugs Advisory Committee for the New Drug Application (NDA) for tofersen, an investigational product for the

January 6, 2023
A statement from Biogen on LEQEMBI™ pricing

Biogen would like to commend our collaboration partner, Eisai, on today's U.S. Food and Drug Administration approval of LEQEMBI TM via the Accelerated Approval pathway. Additional details can be found in a news release announcing the approval. An additional news release from Eisai on patient safety